Welcome to our dedicated page for PMGC Holdings SEC filings (Ticker: ELAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PMGC Holdings Inc. filings document material events, subsidiary announcements, capital-structure disclosures, material agreements, governance matters, and Nasdaq-listed common stock information. Recent Form 8-K reports include Regulation FD disclosures and press-release exhibits related to NorthStrive Biosciences, NorthStrive Defense Tech, AGA Precision Systems, SVM Machining, Pacific Sun Packaging, and corporate financing activity.
The company’s regulatory record identifies PMGC as a Nevada corporation with common stock listed on The Nasdaq Stock Market under the symbol ELAB and as an emerging growth company. Filing categories also cover shareholder voting matters, operating and financial results, security-structure information, and subsidiary-level developments involving manufacturing agreements, intellectual property, packaging markets, and defense technology initiatives.
PMGC Holdings Inc. furnished an Information Statement to report shareholder actions taken by written consent on April 23, 2026. The Majority Shareholders approved an amendment to the 2025 Equity Incentive Plan to increase plan shares to 1,112,636 and approved a Certificate of Amendment to raise authorized capital to 1,500,000,000 shares (1,000,000,000 Common; 500,000,000 Preferred). The Written Consent was adopted by holders of 40 Common shares and 6,372,874 Series B Preferred shares, representing approximately 58.37% of voting power as of the April 23, 2026 record date. The corporate actions will be effective no earlier than twenty calendar days after mailing of the Information Statement and, for the Authorized Shares Increase, at a time set by the CEO in his discretion subject to the stated conditions.
PMGC Holdings Inc., through its wholly owned subsidiary NorthStrive Biosciences Inc., reported that NorthStrive has filed a new U.S. patent application covering its EL-22 myostatin-engineered probiotic for human pharmaceutical use. The application (U.S. Application No. 19/655,160) focuses on formulated products, dosing regimens and protections for treating a broad range of muscle-wasting conditions, including sarcopenia, muscle disuse atrophy and certain neurological disorders. This filing builds on earlier EL-22 intellectual property aimed at muscle preservation and growth, including in patients receiving GLP-1 receptor agonist weight-loss treatments, and is intended to strengthen NorthStrive’s muscle health therapeutics portfolio.
PMGC Holdings Inc. informed shareholders that its Majority Shareholders approved, by written consent, entry into an equity line of credit and related Transaction Documents that permit up to $40,000,000 of aggregate Pre-Paid Purchases. The company completed an Initial Pre-Paid Purchase with an original principal balance of $10,730,000, received net proceeds of $9,927,380, and delivered 262,467 Registered Shares for $1,000,000. The Written Consent authorizes issuances in excess of Nasdaq Listing Rule 5635(d) limits; issuances subject to a 20-calendar-day waiting period after mailing. Shares outstanding as of the Record Date were 4,188,080 common and 6,372,874 Series B preferred.
PMGC Holdings Inc. furnished an Information Statement reporting that holders with a written consent approved two corporate actions: an amendment to the 2025 Equity Incentive Plan increasing plan authorizations to 1,112,636 shares, and an amendment to the Articles of Incorporation increasing authorized capital stock to 1,500,000,000 shares (1,000,000,000 Common; 500,000,000 Preferred).
The Written Consent was adopted by shareholders holding a majority of the voting power as of the Record Date of April 23, 2026. The consenting holders reported ownership of 40 shares of Common Stock and 6,372,874 shares of Series B Preferred Stock, representing approximately 58.37% of voting power. The Information Statement notes that the corporate actions will not be implemented until at least 20 calendar days after mailing under Rule 14c-2, and that the timing for filing the Certificate of Amendment to effect the authorized-share increase is to be set by the CEO in his sole discretion subject to stated conditions.
PMGC Holdings Inc., through its wholly owned subsidiary NorthStrive Defense Tech LLC, furnished information that the subsidiary has secured an exclusive option agreement on a proprietary, U.S.-patented autonomous drone navigation technology for GPS-jammed, spoofed, and denied environments.
The option covers an exclusive license in the aerospace and defense technologies field for specified patent rights tied to U.S. Patent No. 12,277,716 B2, plus a non-exclusive license to related know-how. NorthStrive plans to evaluate the technology, validate defense and counter-drone use cases, and may negotiate a definitive licensing agreement, though there is no guarantee the option will be exercised or that commercialization will succeed.
PMGC Holdings Inc., through its subsidiary SVM Machining, Inc., filed an 8-K to share a press release about a new long-term supply agreement with Turbo-Jet Products Co., Inc. SVM will supply mission-critical aerospace and defense components under a framework covering purchase orders during the agreement’s term.
The agreement has an initial five-year term with provisions for annual renewals, supporting a strategic supply relationship. This is the third long-term agreement signed by a PMGC subsidiary in 2026. SVM is ITAR-registered as of March 20, 2026 and is pursuing AS9100 certification to expand its role in regulated defense programs.
PMGC Holdings Inc. is registering $7,793,112 of Common Stock for issuance and resale related to a Purchase Agreement with Streeterville Capital, LLC. The transaction includes 262,467 Registered Shares delivered for $1,000,000 and additional Pre-Paid Purchase Shares equal to $6,793,112 of remaining shelf capacity. The Purchase Agreement contemplates an equity purchase facility (ELOC) of up to $40,000,000 and a computed Pre-Paid Purchase price of $10,000,000 (after an OID and transaction expenses). The Company received net proceeds of $9,727,380 at consummation and agreed to a placement fee of 8.0% to Univest. The prospectus supplement also notes management’s going-concern uncertainty as of the latest fiscal year-end.
PMGC Holdings Inc. notified shareholders that majority holders approved an equity line of credit (the "ELOC") and related Transaction Documents permitting up to $40,000,000 of Pre-Paid Purchases. The company closed an Initial Pre-Paid Purchase with an original principal of $10,730,000 (initial cash proceeds of $10,000,000) and delivered 262,467 Registered Shares for $1,000,000. The First Pre-Paid Purchase matures on July 16, 2027, includes a $700,000 OID, and limits Investor beneficial ownership to 9.99%. The Company reserved 7,500,000 shares for issuances under the Purchase Agreement. Shares outstanding were 4,188,080 Common and 6,372,874 Series B Preferred as of record dates in April 2026; the ELOC issuances may dilute existing holders and are subject to Nasdaq Listing Rule 5635(d) approval procedures.
PMGC Holdings Inc. entered into a $40,000,000 equity purchase facility with an institutional investor using a pre-paid purchase structure for its common stock. The initial pre-paid purchase has a $10,730,000 principal amount, a $700,000 original issue discount, and a $30,000 transaction expense payment to the investor.
On the closing, the company receives an initial $10,000,000 plus $1,000,000 for 262,467 registered shares and expects net cash proceeds of $9,727,380 after fees. Additional pre-paid purchases during a commitment period running to as late as April 16, 2028 may carry a 7% original issue discount and 7% annual interest, with a per-share floor price tied to the Nasdaq minimum price.
The investor receives a right to participate in up to 10% of future debt or equity financings and agrees to a weekly sales cap of 15% of the stock’s total weekly dollar trading volume. PMGC’s operating subsidiaries guarantee the obligations, and the facility is secured by pledged equity interests in current and future subsidiaries, supported by a 7,500,000-share reserve for issuances.
PMGC Holdings Inc. reported that its subsidiary AGA Precision Systems has signed a second long-term supply agreement to manufacture aerospace and defense components for a globally recognized Tier 1 customer. The multi-year agreement formalizes an existing relationship and will govern future purchase orders.
The deal underscores AGA’s ITAR-registered and AS9100-certified precision CNC capabilities and its growing role as a qualified supplier in the U.S. defense supply chain. Management highlights that such long-term agreements can support operational visibility and recurring revenue potential, although the customer’s identity and commercial terms are not disclosed.
The company notes that it will provide additional information if the agreement becomes material under securities laws and reminds readers that statements about future performance and benefits are forward-looking and subject to risks described in its recent Annual Report on Form 10-K.